Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Patel

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2026
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)L W Martin, X Wang, D Kozono, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2013
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)J R Brahmer, J W Lee, A M Traynor, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2026
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)L W Martin, X Wang, D Kozono, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2013
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)J R Brahmer, J W Lee, A M Traynor, et al.
Pageof 2